Analysis of the Pathophysiology and Pathology of Corona Virus Disease 2019 (Pa-COVID-19)

Conditions

U07.1

Wang Z, Cryar A, Lemke O, Tober-Lau P, Ludwig D, Helbig ET, Hippenstiel S, Sander LE, Blake D, Lane CS, Sayers RL, Mueller C, Zeiser J, Townsend S, Demichev V, Mülleder M, Kurth F, Sirka E, Hartl J, Ralser M.

2022-06-0925 citations

10.1016/j.eclinm.2022.101495

Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19).

Kurth F, Roennefarth M, Thibeault C, Corman VM, Müller-Redetzky H, Mittermaier M, Ruwwe-Glösenkamp C, Heim KM, Krannich A, Zvorc S, Schmidt S, Kretzler L, Dang-Heine C, Rose M, Hummel M, Hocke A, Hübner RH, Opitz B, Mall MA, Röhmel J, Landmesser U, Pieske B, Knauss S, Endres M, Spranger J, Mockenhaupt FP, Tacke F, Treskatsch S, Angermair S, Siegmund B, Spies C, Weber-Carstens S, Eckardt KU, Schürmann D, Uhrig A, Stegemann MS, Zoller T, Drosten C, Suttorp N, Witzenrath M, Hippenstiel S, von Kalle C, Sander LE.

2020-06-1379 citations

10.1007/s15010-020-01464-x

Interventions

Group 1: Patients with laboratory proven COVID-19 Primary and secondary pathophysiological changes and organ function as well as clinical intervention and potential biomarkers and surrogate markers

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Proven infection with SARS-CoV-2 (positive pathogen testing). - Willingness to participate in the study.

Exclusion criteria

Exclusion criteria: - Refusal to participate by patient, parent or appropriate legal representative. - Any conditions that prohibit supplemental blood-sampling.

Design outcomes

Primary

Measure	Time frame
WHO scale for clinical improvement on day 15	—

Secondary

Measure	Time frame
WHO scale for clinical improvement at discharge from hospital	—

Countries

Germany

Contacts

Public ContactFlorian Kurth

Charité - Universitätsmedizin Berlin

florian.kurth@charite.de+4930450553052

Outcome results

None listed